Bgb-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: A phase I/II trial in progress.
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: tislelizumab, TIM-3, PD-1, immune checkpoint blockade, combination immunotherapy, advanced solid tumors, antibody-dependent phagocytosis, Fc gamma receptor, T cell exhaustion, anticancer activity, safety and tolerability, pharmacokinetics, recommended phase 2 dose, tumor-infiltrating lymphocytes, tumor immune microenvironment
Open Access status: closed
OpenAlex ID: W3029023398
